Loading... Please wait... Loading... Please wait...
ESTIMATED
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.57 | $1.57 | $1.57 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
Tekla Life Sciences Investors last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of -225,192 for the quarter and had revenue of 23.52 M for the year. Tekla Life Sciences Investors has generated $1 earnings per share over the last year ($0.83 diluted earnings per share) and currently has a price-to-earnings ratio of 10.05. Tekla Life Sciences Investors has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/29/2024 | Q2 2024 | $1.84 | $-225,192 | $-225,192 | 09/28/2023 | Q4 2023 | -$0.43 | $29.56 M | $29.56 M | 03/30/2023 | Q2 2023 | $1.29 | $9.82 M | 12/30/2022 | Q1 2023 | $0.64 | $965 | 09/29/2022 | Q4 2022 | -$1.10 | $21.69 M | 06/29/2022 | Q3 2022 | -$0.55 | $792 | 03/30/2020 | Q2 2020 | $1.29 | $2.18 M | 09/29/2019 | Q4 2019 | -$1.33 | $1.31 M | 03/31/2019 | Q2 2019 | $0.00 | $0 | 09/29/2018 | Q4 2018 | $2.12 | $988,760 | 03/31/2018 | Q2 2018 | $0.00 | $0 | 09/29/2017 | Q4 2017 | $1.90 | $891,490 |
|---|
A. Tekla Life Sciences Investors has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. The conference call for Tekla Life Sciences Investors's latest earnings report can be listened to online.
A. The conference call transcript for Tekla Life Sciences Investors's latest earnings report can be read online.
A. Tekla Life Sciences Investors (NYSE:HQL) has a recorded annual revenue of $23.52 M.
A. Tekla Life Sciences Investors (NYSE:HQL) has a recorded net income of $23.52 M. Tekla Life Sciences Investors has generated $0.83 earnings per share over the last four quarters.
A. Tekla Life Sciences Investors (NYSE:HQL) has a price-to-earnings ratio of 10.05 and price/earnings-to-growth ratio is 0.08.
